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Abstract
Migraine is a common neurological disorder characterized by nausea, vomiting, photophobia, aching, fever, pain and chills. Triptans are selective serotonin agonists 
which can used to relieve migraine symptoms.  Almotriptan malate and naratriptan hydrochloride are currently used for the management of migraine in the form 
of oral tablets. Oral tablets may be problematic for patients experiencing nausea and vomiting which are often associated with migraine. The microneedle-assisted 
transdermal drug delivery of these triptans may improve patient compliance. A vertical six-celled, static Franz diffusion cell system was used to conduct in vitro 
permeation experiments on porcine ear skin to determine the influence of microneedle-assisted transdermal delivery of both almotriptan malate and naratriptan 
hydrochloride. HPLC-MS analysis was performed using an Agilent 1200 series high performance liquid chromatography system in combination with an Agilent 
time of flight mass spectrometer (TOF-MS) system model 6230 (Agilent, Santa Clara, CA, USA). A reversed phase liquid chromatography column (Agilent Zorbax 
Eclipse Plus C18, 100 mm X 2.1 mm, 3.5 µm), was utilized for chromatographic separation. Confocal laser scanning microscopy was used to characterize the depth 
of the microchannels created after stainless-steel microneedle roller application. Transdermal flux of both triptans was calculated from the linear portion of the 
cumulative amount of drug permeated versus time curve. The mean passive flux of almotriptan malate was 13.044 ± 0.32 µg.cm2.h, while the mean flux following 
microneedle roller application was 11.281 ± 0.22 µg.cm2.h.  The mean flux values for naratriptan hydrochloride for passive and after microneedle roller application was 
0.88 ± 0.29 µg.cm2.h and 4.18 ± 1.39 µg.cm2.h, respectively.  Statistical analysis was performed using the Student’s t-test (GradPad Prism 7). A statistically significant 
difference (p<0.05) between microneedle-treated porcine skin samples compared to untreated skin samples was found for the transdermal flux values of naratriptan 
hydrochloride. Solid stainless-steel microneedle rollers enhanced the transdermal delivery of naratriptan hydrochloride. In contrast, transdermal flux values obtained 
for almotriptan malate indicate that differences between microneedle-treated and untreated skin samples was not statistically significant (p>0.05). 
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Introduction
Migraine is a common neurological disorder that affects 
numerous individuals nationwide [1]. Females are three times more 
likely to suffer from migraine in comparison with males and the 
disorder is more prevalent in individuals between the ages of 25 and 
55 years [2,3]. Symptoms of migraine include: nausea, vomiting, 
photophobia, aching, fever and chills. Migraines are usually due to 
cranial vasodilation and/or the release of pro-inflammatory sensory 
neuropeptides from the trigeminal system [4]. Although not much 
is known about the etiology of migraine current studies indicate that 
the pathophysiology of the disorder maybe linked with both neural 
and vascular mechanisms. Activation of the trigeminovascular system 
triggers the release of vasodilators which contribute to the headache 
associated during a migraine [4]. Vasoactive neuropeptides induce 
vasodilation and are located within the trigeminal neurons. Vasoactive 
neuropeptides mediating vasodilation include: calcitonin gene-related 
peptide (CGRP), substance P, and neurokinin A [5]. CGRP is the 
most critical neuropeptide involved in the generation of migraine [4]. 
The release of vasoactive neuropeptides from the trigeminal nerve 
terminals induces inflammatory reactions in the meningeal blood 
vessels [4]. Further, the association of 5-hydroxytrptamine (5-HT) 
and migraine pathophysiology is supported by the increasing levels 
of 5-hydroxyindoleacetic acid, a major metabolite of 5-HT, during a 
migraine [5].  
Increased understanding of the role 5-HT receptors play in regard 
to migraine has led to the development of new medications such as 
triptans. Triptans are serotonin 5-HT 1B and 1D receptor agonists 
and can be used to for the management of migraine [5]. Triptans work 
by binding to selective serotonin receptors like the 5-HT 1B and 1D 
receptors [5]. The 5-HT 1B receptors are located in the intracranial 
blood vessels within smooth muscle cells while the 5-HT 1D receptor 
is expressed in the trigeminal nerve fibers [4]. The activation of these 
receptors is believed to produce cranial vasoconstriction and provide 
pain relief [5]. Triptans have three modes of action which contribute to 
their anti-migraine effects [6]. These effects include: vasoconstriction of 
intracranial extracerebral vessels, inhibition of vasoactive neuropeptide 
release by the trigeminal terminals, and nociceptive neurotransmission 
inhibition [6].  
Triptans are commonly available as tablets for oral administration 
[7]. However, many migraine patients fail to comply with oral 
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triptans because oral treatments may be ineffectual for patients who 
are experiencing nausea, vomiting, and gastric-stasis which are often 
associated with migraine [6]. This will interfere with the oral drug 
absorption and even delay the initial use of the oral medication [7]. 
Due to the limitations of oral triptans transdermal drug delivery 
will be a more viable option [7]. The long-term goal is to develop a 
microneedle-assisted transdermal system for the delivery of both 
triptans: almotriptan malate and naratriptan hydrochloride. 
There are several advantages of transdermal drug delivery which 
include: avoidance of gastrointestinal irritation, prevention of the first-
pass effect, and the provision of stable drug plasma concentration over 
a sustained period of time [5]. In addition, transdermal delivery also 
provides a pain-free mode of drug administration. However, not all 
drugs are suitable for transdermal delivery [8]. For a drug to cross the 
skin barrier and be delivered into the bloodstream, it must have certain 
physicochemical properties such as low molecular weight, optimal 
partition and diffusion coefficients, including appropriate temperature 
and pH [9]. The greatest drawback of transdermal delivery systems is 
the poor permeability through the stratum corneum [10]. 
The stratum corneum (SC) is the main penetration barrier in 
transdermal drug delivery [10]. It is the outermost layer of the epidermis 
and consists of 15-20 layers of corneocytes which are embedded 
in a lipid matrix [10,11].  The aqueous pores in the hydrophilic 
regions of the SC help to facilitate the transcutaneous diffusion of 
penetrants [12]. There are several ways of overcoming the SC barrier 
including sonophoresis, iontophoresis, prodrugs, microemulsions and 
microneedles (MN) [10,13].  
MNs are micron-sized needles that can facilitate the skin 
penetration of medications by creating micropores which increase 
transdermal diffusion of drugs [14]. The application of MN allows for 
painless penetration of the SC barrier which is appealing to patients 
with needle-phobias because MN does not stimulate the nerves 
associated with pain [11]. A common disadvantage of MN is that only 
small amount of the drug can be given each time of administration 
compared to when using hypodermic needles. MN have been fabricated 
in a range of different sizes, shapes, and materials [8]. There are five 
different types of MN which include: solid, coated, dissolving, hollow, 
and hydrogel-forming [10,11,15]. When using solid MN the drug is 
applied to the skin after creating micro-pores across the skin [11,13]. 
MN can also be coated with the drug, where the drug is dissolved off 
and then the MN are removed [11]. MN can be completely dissolving 
into the skin where the drug is encapsulated within microneedle and 
released upon insertion into skin [11]. Alternatively, hollow MN can be 
used to inject liquid drugs into the skin through a needle bore [11,13]. 
Hydrogel-forming MN facilitate drug delivery by controlled swelling 
of the MN patch arrays and upon swelling the drug is released [13]. 
We will be using solid microneedles for the transdermal delivery of 
almotriptan malate and naratriptan hydrochloride across porcine 
ear skin. Microneedle-assisted transdermal delivery can potentially 
enhance the skin permeability for drug compounds and may lead to 
a statistically significant increase in transdermal flux values for both 
almotriptan malate and naratriptan hydrochloride. 
Almotriptan malate is a sulfonamide triptan which has shown to 
be effective in treating migraines with or without aura [2]. It is sold 
under the brand name Axert and has the molecular weight of 333.465 
g/mol [16]. Almotriptan malate selectively binds to and activates 
serotonin 5-HT 1B and 1D receptors, which are localized in the central 
nervous system [6]. This triggers intracranial blood vessel constriction 
which relieves the pain associated with a migraine [2]. Similar to other 
triptans, almotriptan malate induces vasoconstriction by acting on the 
5-HT 1B receptors and inhibits nociceptive transmission by activating 
the 5-HT 1D receptors [3]. Almotriptan malate’s effect on nociceptive 
transmission contributes to the efficacy on pain transmission, but also 
its effect in improving associated symptoms such as including nausea, 
vomiting, or photophobia [3]. A transdermal delivery system for 
almotriptan malate may provide benefits that oral dosage forms do not. 
Naratriptan hydrochloride is another triptan drug utilized for 
the treatment of migraines. The brand name is Amerge and it has the 
molecular weight of 335.464 g/mol [17]. This triptan acts as a selective 
agonist for 5-HT 1B and 5-HT 1D receptors involved in mediating 
vascular constriction which provides pain relief from migraine 
[2].  Activation of the 5-HT 1B and 5-HT 1D receptors located in 
the sensory nerves of the trigeminal system results in the inhibition 
of vasoactive neuropeptide release which helps to relieve migraine 
symptoms [2]. Naratriptan hydrochloride is well absorbed, with a 74% 
oral bioavailability and has a long half-life of approximately six hours 
[7]. This triptan may help improve patient compliance if constructed 
into a transdermal patch.  
Porcine ear skin was used as a substitute for human skin due to 
similar skin properties. The SC thickness for porcine at 21-25 µm is 
comparable to the SC thickness for human skin at 10-25 µm [18-
20]. Density of hair follicles between porcine skin and human 
skin was 20/cm2 and 14-32/cm2, respectively [19,21]. Porcine skin 
is inexpensive and has shown prior reliability for in-vitro skin 
permeation studies [22]. 
The influence of stainless-steel microneedle rollers on the 
transdermal delivery of almotriptan malate and naratriptan 
hydrochloride across pig ear skin in-vitro was studied. It was 
hypothesized that microneedle-assisted delivery of both triptans will 
enhance the transdermal flux.
Materials and Methods
Materials
Almotriptan malate, naratriptan hydrochloride, phosphate buffer 
saline (PBS, pH 7.4) were purchased from Sigma Aldrich Co. (St. Louis, 
MO, USA). PBS was used as a reconstitution agent for almotriptan 
malate and naratriptan hydrochloride. The NanoPure Infinity 
Ultrapure water system (Barnstead, Dubuque, IA, USA) was used to 
obtain deionized water for all experiments. Stainless-steel microneedle 
rollers with a density of 192 microneedles and microneedle length of 
500 µm were obtained from Pearl Enterprises LLC (Lakewood, NJ 
USA). Raw porcine ears were purchased from Pel- Freez Arkansas LLC 
(Rogers, AR, USA) and allowed to thaw at room temperature before 
experimental use. 
Methods
Skin Preparation: The Institutional Animal Care and Use 
Committee (IACUC) and Institutional Biosafety Committee (IBC) 
of Touro University, Mare Island-Vallejo, CA, USA approved the 
experiments. Raw porcine ears were purchased, thawed and carefully 
shaved using an electric hair clipper. An electric dermatome was 
utilized (Nouvag®, Goldach, Switzerland) to prepare split-thickness 
skins and the Digimatic Micrometer (Mitutoyo, Tokyo, Japan) was 
used to measure the thickness of the porcine samples. The dermatomed 
skin samples obtained were individually enclosed in aluminum foil and 
plastic bags and stored at -20 °C until further use. 
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In-vitro Diffusion Studies:  A vertical six-celled Franz diffusion 
system (PermeGear, Hellertown, PA, USA) was utilized to conduct 
transdermal permeation studies. The six cells consisted of a top donor 
compartments and lower receptor compartments. To help maintain 
uniform drug distribution the receptor cells were magnetically 
stirred. Each of the six cells also consisted of a sampling port and a 
circulating water jacket at 37 °C to simulate human body temperature 
(ThermoFisher Scientific, Waltham, MA, USA). The Franz diffusion 
cells had a diffusion area of 1.77cm2 a receptor volume of 12mL filled 
with PBS. 
Microneedle-treated and untreated porcine ear skin samples were 
used for this experiment. To prepare microneedle-treated samples 
a stainless-steel microneedle roller was applied to porcine skins to 
create microchannels. To create microchannels in the skin samples 
the microneedle roller was applied 15 times to each skin sample 
in the vertical, diagonal, and horizontal directions. The roller was 
applied and measured at a force of 20lbs using a weighing scale. Three 
of six compartments of the Franz diffusion cell system contained 
microneedle treated skin samples while the remaining three consisted 
of untreated samples, serving as controls. Porcine ear skins were 
mounted between the upper donor and lower receptor compartments. 
Vacuum grease was utilized (Dow Corning, Midland, MA, USA) along 
with a metal clamp to help hold the porcine samples stay in place and 
prevent loss of triptan solution. Skin samples were placed with the 
stratum corneum surface facing towards the donor cell. Diffusion 
experiments for both triptans were replicated six times each (n=6) and 
each experiment was conducted out using 1 mL of either almotriptan 
malate or naratriptan hydrochloride. The triptan was placed on porcine 
skin samples using 1 mL syringes through the donor compartment. To 
help reduce evaporation the donor compartments and sampling ports 
were covered with parafilm and aluminum foil. At intervals of 2 hours 
for a 12-hour period, 1mL aliquots of the receptor solution were taken 
using 1 mL syringes. Collected solutions were placed in vials from 
Agilent Technologies (Agilent, Santa Clara, CA) and stored in 4°C 
until shipment to the University of Idaho for high performance liquid 
chromatography-mass spectrometry (HPLC–MS) analysis. After each 
extraction receptor compartments were refilled with an equal volume 
of fresh PBS (1mL). Using the collected HPLC-MS data the cumulative 
amount of drug permeated was plotted as a function of time for 
both triptans. The slope of the steady state portion of the cumulative 
amount of drug permeated over time was used to further calculate the 
transdermal flux values. 
HPLC/DAD/TOF-MS Analysis of Pharmaceuticals: Quantitative 
analysis of the drug concentrations in the samples collected was carried 
out using HPLC-MS analysis. HPLC-MS analysis was performed using 
an Agilent 1200 series liquid chromatography system in combination 
with an Agilent time of flight mass spectrometer (TOF-MS) model 
6230 (Agilent, Santa Clara, CA, USA). Chromatographic separation 
was achieved using a reversed phase liquid chromatography column 
(Agilent Zorbax Eclipse Plus C18, 100 mm X 2.1 mm, 3.5 µm) with 
temperatures maintained at 30°C (Agilent, Santa Clara, CA, USA). The 
mobile phase consisted of 0.1% formic acid in acetonitrile. From 3 to 
20% there was a linear gradient in 3 min followed by an increase to 
100% in 2 min. Equilibration at 3% was subsequently carried out for 
5 min. The mobile phase flow rate was 0.3 mL min-1 with an injection 
volume of 5 µL.  The reconstructed ion current mode with a m/z of 
336.16 was used to perform quantification of both triptans. 
Microchannel Depth Characterization by Confocal Laser 
Scanning Microscopy (CLSM): CLSM was performed at the Van 
Winkle Lab housed in the Center for Health and the Environment 
of the University of California, Davis to characterize the depth of 
the microchannels created by the stainless-steel microneedle roller. 
Confocal images were taken of both microneedle-treated and untreated 
skin samples. After the microneedle roller application, porcine samples 
were treated with 200 uL of fluorescent dye, Alexaflour 594 (Thermo 
Fisher Scientific, Waltham, MA, USA). The sample was then blotted 
with Kimwipes (Kimberly-Clark Professional, Roswell, GA, USA) to 
remove excess dye. Strips of microneedle-treated porcine skin were 
cut into sections, embedded with OCT medium (Sakura Finetek Inc., 
Torrance, CA, USA) and placed onto Tissue-Tek Cryomolds (Sakura 
Finetek Inc., Torrance, CA, USA). All samples were cryosectioned to 
10 µm thick vertical sections using a Leica CM1950 Cryostat (Leica 
Biosystems, Buffalo Grove, IL, USA) and transferred onto glass slides 
in preparation for CLSM. Confocal images of microneedle-treated and 
untreated skin samples taken using a Leica TCS LSI laser scanning 
confocal microscope. The frame was set at 1024 X 1024 pixels with a 
magnification of 5X. Excitation was carried out at 590 nm and emission 
at 617 nm. Untreated porcine samples were also treated with Alexaflour 
594, cryosectioned and examined using the Leica TCS LSI confocal 
laser scanning microscope.
Data Analysis: The transdermal flux of both triptans was 
determined from the slope of the average cumulative amount versus 
time curve. For each drug experiments were replicated six times and 
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For the Hayton–Chen equation,  is the corrected concentration 
and Cn is the measured concentration in the nth sample. VT  stands for 
the total volume of the receptor fluid (12 mL) and  VS is the volume of 
sample withdrawn from the receptor fluid (1 mL). 1 1nC −  represents the 
corrected concentration in (n-1)th sample while 1nC −  is the measured 
concentration in (n-1)th sample. 
Statistical Analysis: GraphPad Prism 7 (GraphPad Software, Inc., 
La Jolla, CA, USA) was used to perform statistical analysis. Results with 
a p-value of less than 0.05 was considered to be statistically significant. 
To plot the graphs, the average replicates (n=6) with corresponding 
standard deviation was used for both almotriptan malate and 
naratriptan hydrochloride (Table 1). 
Results 
Microchannel Formation
Confocal laser scanning microscopy was used to compare both 
microneedle-treated and untreated skins. Untreated porcine skin 
samples were used as controls to compare against microneedle-treated 
Solution Name Passive (µg/cm2/h) Microneedle (µg/cm2/h) P- Value
Naratriptan 
hydrochloride 0.881 ± 0.293 4.187 ± 1.396 0.0054
Almotriptan malate 13.044 ± 0.32 11.281 ± 0.22 0.6053
Table 1. Transdermal flux (µg/cm2/h ± SD) of naratriptan hydrochloride and almotriptan 
malate following microneedle roller application. Passive flux values served as controls (n = 6)
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samples and determine whether microchannels were formed after 
microneedle roller application. Figure 1A shows the formation of a 
microchannel after being treated with microneedle rollers. It is visible 
that the microneedle roller successfully penetrated the stratum corneum 
to create micropores in the skin which were visible with Alexaflour 
594 fluorescent dye. The pore constructed by the microneedle roller is 
displayed in Figure 1A with a microchannel depth of 215 µm. Unlike 
Figure 1A, the untreated porcine skin displayed in Figure 1B displays 
no microchannels.
In-vitro Diffusion Study
Transdermal flux of both naratriptan hydrochloride and almotriptan 
malate was calculated from the linear portion of the cumulative amount 
versus time curve. The flux for naratriptan hydrochloride across 
microneedle-treated pig skin was 4.18 ± 1.39 µg.cm2.h while the flux 
for passive diffusion was 0.88 ± 0.29 µg.cm2.h. There was a statistically 
significant difference (p<0.05) in the transdermal flux values of 
naratriptan hydrochloride across microneedle-treated porcine samples 
compared to passive diffusion. Passive penetration rates for naratriptan 
hydrochloride were low compared to microneedle therefore solid 
stainless-steel microneedles enhanced the transdermal delivery of this 
drug. Meanwhile, for the permeation profile of almotriptan malate 
there was not a statistically significant difference between microneedle-
treated and untreated samples. The passive and microneedle-treated 
flux obtained for almotriptan malate was 13.044 ± 0.32 and 11.281 ± 
0.22, respectively (Figure 2).
Discussion
In this paper, the effect of microneedles on the percutaneous 
transport of almotriptan malate and naratriptan hydrochloride were 
investigated. Microchannel visualization with confocal microscopy 
confirmed that the microneedle roller was successfully able to 
penetrate the skin. Banga, et al. reported that the application of a 
microneedle roller creates microchannels in the skin allowing for 
enhanced transdermal drug delivery [23]. Methylene blue staining 
and histological sectioning were used to confirm microchannels 
while confocal laser scanning microscopy was used to characterize 
microchannel depth after microneedle roller application [23]. In our 
project, confocal microscopy images confirmed that the stainless-steel 
microneedle roller was capable of overcoming the skin barrier to create 
microchannels across porcine skin [24]. Confocal images comparing 
microneedle-treated and untreated skin samples indicate that 
microchannels were created following the application of a microneedle 
roller (Figure 3).  However, despite microchannel formation there was 
no statistically significant increase in the percutaneous absorption for 
almotriptan malate. The difference between microneedle-treated 
and passive flux values of almotriptan malate was not statistically 
significant (p<0.05). 
Triptans are commonly taken orally in the form of tablets. Patients 
with chronic migraine take medications more than once a day [7]. 
Almotriptan malate is available in 6.25mg tablets with a maximum 
daily dosage of 25mg while naratriptan hydrochloride tablets are 
available in 1mg or 2.5mg tablets with a maximum daily dosage of 
5mg [7]. However, due to the symptoms associated with migraine 
such as pain, vomiting, and nausea many times patients are unable 
to ingest tablets orally. Other disadvantages include the presystemic 
metabolism, degradation by enzymes and acid in the stomach, and 
erratic absorption [8]. Therefore, a microneedle transdermal delivery 
system would be useful in improving patient compliance. Arya et al. 
also tested dissolving microneedle patches on human subjects and 
found that the patches were well tolerated with no pain and swelling, 
and self-administration rates of microneedle patches were high [25].  A 
larger phase 1 clinical study conducted on 100 human subjects tested 
the efficacy of dissolving microneedles to deliver influenza [26]. It was 
found that the found that vaccine delivery using a microneedle patch 
was similar to that of when using a hypodermic needle [26]. Needle-
phobia is a challenge with many patients and having a microneedle patch 
would be would be beneficial. Arya et al. also reported that the microneedle 
patch was preferred by patients over a hypodermic needle [25]. 
For almotriptan malate, the difference in flux values between 
microneedle-treated and passive was not statistically significant 
(p<0.05). Several factors may have impacted this occurrence. The 
effectiveness of a microneedle-assisted transdermal delivery system 
is dependent on the properties of the skin, the microneedles, and the 
drug. Since drug entry is imposed by skin permeability the interaction 
of a specific drug and the skin varies; this is an important factor to 
be considered.  Physiochemical properties of the compound such as 
molecular weight, drug concentration, pH, melting point, and partition 
coefficient all influence the rate of transdermal drug delivery. Small 
molecular weight compounds penetrate at a faster rate that larger ones, 
therefore having a molecular weight of less than 500 Daltons is typically 
needed to cross the stratum corneum. The human skin consists of a 
lipid rich bilayer which makes it necessary for compounds to have 
both aqueous and lipid solubilities. An ideal transdermal drug delivery 
candidate would have an aqueous solubility of greater than 1 mg/
mL, partition coefficient (log P) between 1-3, point of less than 200 
°C [27]. Compounds with log P values below 1 are too hydrophilic to 
A                                                                                      B 
Figure 1. Chemical structures of (A) almotriptan malate and (B) naratriptan hydrochloride
Figure 2. Stainless-steel microneedle roller with microneedles 500 µm in length and 
density of 192 needles
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effectively disrupt the stratum corneum while those greater than 3 are 
too hydrophobic resulting in low therapeutic plasma concentrations 
[27]. The melting point of a compound is indirectly proportional to 
its lipophilicity and solubility in skin lipids [13]. A low melting point 
will allow for faster penetration and optimal transdermal delivery. 
Almotriptan malate has a molecular weight of 335.466 Daltons, 
log P value of 1.6, and a melting point of 170 °C [7]. However, the 
interactions between the drug, microneedles and the skin are complex. 
Several investigators have studied the relationship between the 
physicochemical properties of compounds and skin permeability 
[28,29]. Only a few variables were studied in the Potts-Guy equation 
but currently those variables now include properties such as dipole 
moment and polar surface area [28,29]. Clearly, these are complex 
interactions worthy of further investigation (Figures 4 and 5)
Microneedle length, density, insertion force and time can all 
influence the permeation rates of compounds across the skin. A 
possible explanation of why there was low flux values for microneedle-
treated skin samples for almotriptan malate maybe dependent on 
microneedle length and density. Microneedles that were 500 μm in 
length were used for this study. Increasing the length may increase 
the penetration rate of almotriptan malate. In the study by Nalluri, et 
al. 500 μm and 1000 μm microneedles were compared for the in vitro 
permeation of Levodopa across porcine ear skin [30]. It was found that 
longer microneedle arrays are able to create pores at a greater [30]. The 
use of 500 μm microneedle arrays led to a lower permeation rate of 
levodopa probably due to the inability of the shorter microneedles to 
create deep enough pores [30]. Another study by Li, et al. reported that 
the microneedle-assisted transdermal delivery effectively increased 
antibody delivery when microneedle length, microneedle array, and 
drug concentration were increased [31]. Banga, et al. confirmed that 
an increase in microneedle length from 500 μm to 1100 μm and 1400 
μm enhanced microchannel depth [14]. A greater microneedle depth is 
sometimes associated with increased drug penetration [14]. The results 
showed that an increase in needle length from 500 μm to 1100 μm and 
1400 μm significantly increased microchannel depth in the skin [24].  It 
is important to consider these factors for future studies as this may assist 
in enhancing the delivery of almotriptan malate. The study conducted 
by Calatayud-Pascul, et al. confirmed that therapeutic drug levels for 
almotriptan were obtained using an iontophoresis transdermal delivery 
system [32]. Iontophoresis uses an electrical current to increase drug 
penetration through the skin [32]. For iontophoresis, a compound 
less than 12,000 Daltons can be successfully delivered across the skin 
whereas for microneedle transdermal drug delivery and ideal candidate 
must have a much lower molecular weight [13]. Using iontophoresis 
in combination with microneedles has shown to results in faster drug 
delivery and permeation rates due to both the micropores creates and 
the electrical current pushing the drug into the skin [33]. Possibly 
increasing the concentration of almotriptan malate can enhance 
transdermal permeation however that is again limited because of the 
need for a low molecular weight when using microneedles. Sachdeva 
et al. found that iontophoresis treatment delivered three times more 
drug concentration compared to microneedle treatment [33]. The 
combination of enhancement technologies such as microneedles with 
iontophoresis may prove to be effective for the transdermal delivery of 
almotriptan malate. 
Furthermore, the low flux levels of almotriptan hydrochloride 
across microneedle-treated skin samples may have resulted from 
the “bed of nails” effect. The phenomenon is associated with high 
microneedle density and close needle-to-needle spacing which reduces 
the penetration and efficiency of microneedles [34,35].  Yan, et al. 
A                                                                                                 B
Figure 3. Images of porcine skin samples by confocal laser scanning microscopy (CLSM). (A) Microneedle treated porcine skin showing a single microchannel depth of 215 μm (B) 
Untreated porcine skin
Figure 4. In-vitro cumulative amount versus time curve of naratriptan hydrochloride across 
microneedle-treated and untreated porcine ear skin over 12 hours
Figure 5. Transdermal flux of naratriptan hydrochloride across microneedle-treated and 
untreated porcine ear skin over 12 hours
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studied microneedles densities ranging from 400 to 11,900 needles/
cm2 [36] . Exerting the same force on the microneedle arrays, the study 
found that arrays with less than 2000 needles/cm2 increased drug flux 
greater than higher needle density arrays of 5625 needles/cm2 [36]. It 
has been observed that when microneedle density is high the pressure 
exerted by each microneedle is significantly reduced preventing proper 
penetration [34]. Applying the same force to a microneedle array of 
lower density may have allowed for a greater enhancement of drug flux. 
Unlike almotriptan malate, skin pretreatment with microneedle 
rollers helped to enhance transdermal permeation for naratriptan 
malate. The molecular weight of naratriptan hydrochloride is 371.924 
Daltons, it has a log P value is 1.6, and melting point is 246 °C [7]. 
This indicates that significant amounts of naratriptan hydrochloride 
can be delivered through the skin barrier with microneedles in 
comparison to passive permeation.  Further in-vitro studies are needed 
to determine the influence of variables such as drug concentration, 
microneedle length, density and design, on the transdermal flux of 
these triptans. Solid stainless-steel microneedle rollers were used for 
this experiment. Therefore, it would be interesting to compare flux 
enhancement with different types of microneedles for almotriptan 
malate transdermal delivery instead of solely using solid microneedle 
rollers. The combination of microneedles with other techniques such 
as iontophoresis and sonophoresis may help enhance permeation rates. 
Future in-vivo studies should be performed to test for the efficiency of a 
microneedle-assisted transdermal system for both triptans: almotriptan 
malate and naratriptan hydrochloride (Figures 6 and 7)
Conclusion
This research was carried out to study the influence of 
microneedles on the transdermal delivery of almotriptan malate and 
naratriptan hydrochloride. For naratriptan differences in flux values 
of microneedle-treated and untreated porcine skin samples using 
solid microneedles were statistically significant (p<0.05). Conversely, 
for almotriptan malate there was not a statistically significant increase 
in transdermal flux across porcine skin following the application of a 
microneedle roller (p>0.05). 
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